Scholars Central

Conference abstractPublished 10 Aug 2017

Considerations in biosimilars commercialization

Authors: Darius Panaligan

Merck Group, Switzerland

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The biosimilar market holds significant potential and benefit for all stakeholders. The experience with first wave of biosimilar launches provide interesting and in some cases exciting references for the next wave of more complex biosimilars. What does experience in Europe and US could show us so far about the evolving opportunity in biosimilars? In this talk the challenges and opportunities with commercialization of biosimilars will also be covered.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “Darius Panaligan”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels